Gedea Biotech AB

Gedea Biotech develops pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can be very disturbing and include an often profuse thin, white, fishy smelling vaginal discharge. Standard treatment consists of antimicrobials, but recurrence rate is 1530 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisations top ten threats to global health and research into novel non-antimicrobial based treatments is timely

Antimicrobial resistance,amr,femtech,womens health,and bacterial vaginosis

Gedea biotech ab operates in the Biotechnology research industry.

Gedea biotech ab's revenue is 1m - 10m

Gedea biotech ab has 11 - 50 employees.